Becton Dickinson Microbiology Systems licenses Alamar Biosciences technology:
This article was originally published in Clinica
Becton Dickinson Microbiology Systems is to acquire a semi- exclusive, worldwide licence to Alamar Biosciences' alamarBlue technology. Under a letter of intent signed by the two companies on May 8th, Alamar would receive up to $3.5 million and undisclosed royalties on product sales incorporating the technology. Alamar, which is to merge with AccuMed to form AccuMed International (see Clinica No 652, p 15), says the agreement with Becton Dickinson will double its own distribution capabilities. AccuMed International will retain rights to use the alamarBlue technology in any of its own commercial products.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.